Recently, the genes of components of the renin ± angiotensin system (RAS), namely angiotensinogen (AGT), angiotensin converting enzyme and angiotensin II receptor have been described in adipose tissue. In animal models the angiotensinogen in adipose tissue has been implicated in the pathogenesis of metabolic alterations and hypertension associated with obesity. The aim of our study was to evaluate the AGT gene expression both in visceral and subcutaneous adipose tissue in obese patients and lean subjects. AGT mRNA levels were measured by reverse transcriptase polymerase chain reaction (RT-PCR) using speci®c primers. AGT mRNA was expressed at variable levels in obese patients. It was signi®cantly greater in visceral than in subcutaneous adipose tissue. Positive and signi®cant correlation was found between the expression of AGT in visceral adipose tissue and BMI. These data suggest that angiotensinogen may be determinant of fat distribution and may be involved in the plurimetabolic syndrome of central obesity.
Introduction
The genes of components of the renin ± angiotensin system (RAS), namely angiotensinogen (AGT), angiotensin converting enzyme and angiotensin II receptor, have been found to be expressed in adipose tissue. In animal models RAS has been implicated in the regulation of adipose tissue as differentiation of preadipocyte in adipocyte and induction of key genes for lipogenesis. 1 Moreover it has been suggested that RAS in adipose tissue may play a role in the pathogenesis of metabolic alterations 2 and hypertension. 3 Only a few observations exist concerning the AGT expression in human adipose tissue, whereas a positive correlation between increased plasma renin activity (PRA), plasma angiotensinogen concentration (pAGT), blood pressure (BP) levels and body mass index (BMI) have been found. 4 The aim of our study was to evaluate the AGT gene expression in visceral and subcutaneous abdominal adipose tissue in normotensive and hypertensive obese patients and lean subjects.
Subcutaneous adipose tissue was obtained by needle biopsy in six patients, and both subcutaneous and visceral fat tissue was obtained in 10 patients during surgery for colecystectomy. In all subjects BMI, blood pressure, insulin, PRA and plasma aldosterone levels were evaluated. AGT mRNA levels were measured by comparative RT-PCR using speci®c primers. AGT mRNA levels were standardized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA, and analysed by densitometric scanning. Results are reported as means AE s.d. arbitrary densitometric units.
Results and discussion
Insulin levels (15 AE 11 vs 6.6 AE 3.2 mcUaml), as well as plasma aldosterone (27AE 10 vs 10 AE 4 ngadl), and uric acid (6 AE 1.4 vs 3.8 AE 1.9 mgadl) were signi®-cantly higher in obese patients than control subjects (P`0.05). Blood pressure was higher, but not signi®cantly, in obese patients than in control subjects systolic blood pressure (SBP): 132AE 14 vs 124 AE 14 mmHg; diastolic blood pressure (DBP): 83 AE 7 vs 78 AE 5 mmHg).
In obese patients as well as in lean subjects, the AGT mRNA was signi®cantly higher in visceraladipose tissue than in subcutaneous adipose tissue (0.60 AE 0.2 vs 0.3 AE 0.1, P`0.05) (Figure 1) .
Greater AGT mRNA levels were found in obese patients than in lean subjects, but statistical signi®cance in both subcutaneous (0.35AE 0.19 vs 0.28 AE 0.05) and visceral adipose tissue (0.64AE 0.27 vs 0.54AE 0.20) was not reached between the two groups. In fact, in obese patients the AGT mRNA was expressed at variable levels in visceral adipose tissue.
Signi®cant differences of AGT mRNA were found between obese patients with hypertension and obese patients without hypertension, in subcutaneous adipose tissue (0.19AE 0.05 vs 0.28 AE 0.15, P`0.05). A signi®cant and positive correlation between AGT gene expression, and degree of BMI has been found in visceral, but not in subcutaneous adipose tissue.
Our data show that AGT mRNA is expressed in both human subcutaneous and visceral adipose tissue. This is the ®rst study demonstrating AGT expression in both visceral and subcutaneous adipose tissue in the same patients. The ®nding that AGT mRNA was signi®cantly different in visceral adipose tissue with respect to subcutaneous adipose tissue suggests a different role and a tissue-speci®c regulation of this gene in humans. The higher expression of angiotensinogen in visceral adipose tissue, which is correlated with cardiovascular complications, may support the idea that angiotensin II, produced locally in adipose tissue from AGT, as recently demonstrated, 5 may be involved in the regulation of adipogenesis, and in the development of disease as obesity or, secondary to obesity, as hypertension. Moreover the variable levels of AGT mRNA in obese patients may be correlated with different metabolic conditions of these patients.
The different AGT mRNA gene expression in subcutaneous adipose tissue between obese-hypertensive patients and obese-normotensive patients suggests a down-regulation of this gene by a hypertensive condition. The valuation of all components of the renin ± angiotensin system in these two tissues may provide further clari®cation of the relative importance of this system in adipose tissue in human obesity and hypertension.
